Health
Immunotherapy combination shrinks rare angiosarcoma tumors in 25% of patients – News-Medical.Net
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s Division of Cancer Diagnosis and Treatment,…
Reviewed by Emily Henderson, B.Sc.Nov 15 2020
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute’s (NCI) Division of Cancer Diagnosis and Treatment (DCTD), part of the National Institutes of Health, have shown that the immunotherapy combination of ipilimumab and nivolumab shrinks rare angiosarcoma tumors in 25 percent of all patients, with some having an even stronger response to the drug combination.
Results of the SWOG study, led…
-
Noosa News12 hours agoThe grey backstreet of Brisbane’s Fortitude Valley where Arnie the missing dog was found dead in his owner Nathan McKeown’s black ute
-
General23 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
Business21 hours agoRevenue growth, profit margin pressures, and a $365m buyback
-
Noosa News20 hours agoNT cattle rustler fined almost $430k for stealing 116 head from neighbouring station